Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy

Trial Profile

Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant (Primary) ; Dexamethasone; Dexamethasone; Serotonin 3 receptor antagonists
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms SENRI
  • Most Recent Events

    • 21 Jan 2017 Results of subgroup analysis of SENRI trial (n=370) presented at the 2017 Gastrointestinal Cancers Symposium
    • 04 Jul 2015 Results presented at the 17th World Congress on Gastrointestinal Cancer.
    • 28 Apr 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top